We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$962M
1-Year Est. Return
524.64%
This Fund
S&P 500
This Quarter
Est. Return
+44.51%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$53.9M
(+18%)
Cap. Flow
+$19M
Cap. Flow
% of AUM
5.43%
Top 10 Holdings %
Top 10 Hldgs %
33.5%
Holding
108
New
29
Increased
39
Reduced
21
Closed
18
Avg Time Held Equity + Options
2.6
quarters
Top 10 Avg Time Held Equity + Options
0.8
quarters
Top 20 Avg Time Held Equity + Options
1.2
quarters
Avg Time Held Equity only
2.8
quarters
Top 10 Avg Time Held Equity only
0.8
quarters
Top 20 Avg Time Held Equity only
1.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
+$9.42M |
| 2 |
Nuvalent
NUVL
|
+$7.29M |
| 3 |
Biogen
BIIB
|
+$6.21M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
+$4.88M |
| 5 |
Terns Pharmaceuticals
TERN
|
+$4.56M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Veracyte
VCYT
|
+$10.8M |
| 2 |
APEN
Apollo Endosurgery, Inc.
APEN
|
+$6.26M |
| 3 |
Akero Therapeutics
AKRO
|
+$5.48M |
| 4 |
Cogent Biosciences
COGT
|
+$5.3M |
| 5 |
Nkarta
NKTX
|
+$4.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.01% |
| 2 | Miscellaneous | 16.91% |
| 3 | Technology | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
RXDX
1
PUT
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $19M | 5.43% |
172,400
-32,300
| -16% | -$2.09M |
2022 Q2
2 quarters
|
|
|
2
Madrigal Pharmaceuticals
MDGL
$10.4B
| $14.5M | 4.14% |
+49,898
| New | +$4.88M |
2022 Q4
0 quarters
|
|
|
BLU
3
DELISTED
BELLUS Health Inc.
BLU
| $14M | 4.02% |
1,707,370
+51,595
| +3% | +$481K |
2021 Q2
6 quarters
|
|
4
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $11.8M | 3.38% |
2,230,000
-324,277
| -13% | -$1.48M |
2021 Q4
4 quarters
|
|
|
VRAY
5
DELISTED
ViewRay, Inc.
VRAY
| $10.8M | 3.08% |
2,405,360
+81,294
| +3% | +$354K |
2021 Q2
6 quarters
|
|
6
Xenon Pharmaceuticals
XENE
$3.33B
| $10M | 2.86% |
253,655
+7,663
| +3% | +$279K |
2021 Q3
5 quarters
|
|
|
7
DELISTED
Akero Therapeutics
AKRO
| $9.43M | 2.7% |
172,100
-127,900
| -43% | -$5.48M |
2022 Q2
2 quarters
|
|
8
PUT
Anavex Life Sciences
AVXL
$137M
| $9.33M | 2.67% |
1,007,700
+65,200
| +7% | +$697K |
2022 Q2
2 quarters
|
|
9
Immunovant
IMVT
$5.93B
| $9.22M | 2.64% |
519,614
+219,614
| +73% | +$2.77M |
2022 Q3
1 quarter
|
|
|
10
DELISTED
Nuvalent
NUVL
| $9.02M | 2.58% |
302,963
+261,524
| +631% | +$7.29M |
2022 Q3
1 quarter
|
|
11
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $8.95M | 2.56% |
334,535
+10,114
| +3% | +$276K |
2020 Q4
8 quarters
|
|
12
Alnylam Pharmaceuticals
ALNY
$29.9B
| $8.95M | 2.56% |
37,652
+5,107
| +16% | +$1.09M |
2022 Q3
1 quarter
|
|
|
13
PUT
Madrigal Pharmaceuticals
MDGL
$10.4B
| $8.71M | 2.49% |
+30,000
| New | +$2.93M |
2022 Q4
0 quarters
|
|
|
14
CALL
DELISTED
Akero Therapeutics
AKRO
| $8.22M | 2.35% |
+150,000
| New | +$6.43M |
2022 Q4
0 quarters
|
|
|
15
PUT
DELISTED
Akero Therapeutics
AKRO
| $8.22M | 2.35% |
+150,000
| New | +$6.43M |
2022 Q4
0 quarters
|
|
16
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $7.43M | 2.13% |
140,366
+4,240
| +3% | +$212K |
2020 Q4
8 quarters
|
|
17
Oric Pharmaceuticals
ORIC
$1.17B
| $7.28M | 2.08% |
1,236,296
+27,304
| +2% | +$92.2K |
2022 Q2
2 quarters
|
|
|
18
DELISTED
Terns Pharmaceuticals
TERN
| $7.13M | 2.04% |
700,000
+685,527
| +4,737% | +$4.56M |
2022 Q3
1 quarter
|
|
19
DELISTED
Mersana Therapeutics
MRSN
| $6.68M | 1.91% |
45,607
+5,844
| +15% | +$988K |
2022 Q2
2 quarters
|
|
|
20
Biogen
BIIB
$33.8B
| $6.09M | 1.74% |
+21,975
| New | +$6.21M |
2022 Q4
0 quarters
|
|
21
Cerus
CERS
$455M
| $5.96M | 1.71% |
1,634,014
+17,555
| +1% | +$66.2K |
2021 Q2
6 quarters
|
|
22
CVRx
CVRX
$36.2M
| $5.77M | 1.65% |
314,584
+6,664
| +2% | +$82.2K |
2022 Q2
2 quarters
|
|
23
Aclaris Therapeutics
ACRS
$511M
| $5.55M | 1.59% |
352,193
-191,583
| -35% | -$3.08M |
2021 Q1
7 quarters
|
|
|
RXDX
24
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $5.5M | 1.57% |
+50,000
| New | +$3.24M |
2022 Q4
0 quarters
|
|
|
CINC
25
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $4.86M | 1.39% |
+395,382
| New | +$9.42M |
2022 Q4
0 quarters
|
|
Similar funds
LGP
PL
LAM
ACP
GIG
AAP
BEAM
RAM
Silverarc Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, Silverarc Capital Management held 108 positions worth $350M, up 18% from $296M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Silverarc Capital Management deployed $19M of net new capital in Q4 2022, opening 29 new positions and adding to 39 existing holdings. Its largest new stake was CinCor Pharma, Inc. Common Stock: 395,382 shares worth $4.86M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 80% a quarter earlier, followed by Miscellaneous and Technology.
On the sell side, the largest reduction was Veracyte, an estimated $10.8M trimmed.
- Silverarc Capital Management's largest Q4 2022 buy was CinCor Pharma, Inc. Common Stock: 395,382 shares worth $4.86M.
- Silverarc Capital Management added most to Nuvalent in Q4 2022, an estimated $7.29M increase.
- Silverarc Capital Management's biggest Q4 2022 reduction was Veracyte, cutting an estimated $10.8M.
- Silverarc Capital Management fully exited Apollo Endosurgery, Inc. in Q4 2022, selling an estimated $6.26M.
- Silverarc Capital Management's ten largest holdings make up 33% of its $350M portfolio in Q4 2022.
- Silverarc Capital Management opened 29 new positions and closed 18 in Q4 2022.
- Silverarc Capital Management's portfolio value rose 18% quarter-over-quarter to $350M.
Based on Silverarc Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.